Spots Global Cancer Trial Database for durvalumab
Every month we try and update this database with for durvalumab cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Ph2 Study of Savolitinib and Durvalumab (MEDI4736) Combination in Advanced MET Amplified Gastric Cancer(VIKTORY-2) | NCT05620628 | Stomach Cancer,... | Durvalumab Savolitinib | 19 Years - | Samsung Medical Center | |
| Durvalumab as Maintenance Following Chemoradiation for Unresectable Esophageal Squamous Cell Carcinoma | NCT04054518 | Esophageal Squa... | Durvalumab | 18 Years - | Instituto do Cancer do Estado de São Paulo | |
| Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract Cancer | NCT05239169 | Biliary Tract C... Intrahepatic Ch... Hilar Cholangio... Distal Cholangi... Gall Bladder Ca... | Durvalumab Tremelimumab Capecitabine | 18 Years - | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | |
| Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer | NCT04918186 | Ovarian Cancer | Durvalumab BA3011 BA3021 To be determine... | 18 Years - | Canadian Cancer Trials Group | |
| Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can... | NCT02484404 | Colorectal Neop... Breast Neoplasm... | Olaparib Cediranib Durvalumab | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Durvalumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | NCT02966587 | Castration Leve... Hormone-Resista... Microsatellite ... | Durvalumab Laboratory Biom... | 18 Years - | University of Washington | |
| Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy | NCT03703297 | Small Cell Lung... | Durvalumab Tremelimumab Placebo | 18 Years - 130 Years | AstraZeneca | |
| An Open-label, Phase II Study of AZD4635 in Patients With Prostate Cancer | NCT04089553 | Prostate Cancer Metastatic Cast... | AZD4635 Oleclumab Durvalumab | 18 Years - 130 Years | AstraZeneca | |
| Durvalumab Long-Term Safety and Efficacy Study | NCT04078152 | Solid Tumor | Durvalumab | 18 Years - 130 Years | AstraZeneca | |
| Using Circulating Tumor DNA to Personalize Duration of Consolidation Durvalumab | NCT05757843 | NSCLC, Stage II... | Signatera ctDNA... Durvalumab | 18 Years - | Indiana University | |
| Durvalumab Combined With Chemotherapy and Stereotactic Body Radiotherapy (SBRT) in Patients With Oligometastatic Non-small Cell Lung Cancer (NSCLC) | NCT04255836 | Carcinoma, Non-... | Durvalumab the first line ... stereotactic bo... | 18 Years - 80 Years | Zhejiang Cancer Hospital | |
| A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer | NCT03742102 | Triple Negative... | Durvalumab Capivasertib Oleclumab Paclitaxel Trastuzumab der... Datopotamab der... | 18 Years - 130 Years | AstraZeneca | |
| Neoadjuvant Immunoradiation for Resectable Non-Small Cell Lung Cancer | NCT03237377 | Non-Small Cell ... | Durvalumab Tremelimumab Thoracic Radiat... lobectomy Standard of car... | 18 Years - 100 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| A Phase 2 Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Multi-Cancer Populations With Correlation to Clinical, Molecular and Immunologic Parameters With DNA MethylaTION | NCT04262375 | Non Small Cell ... Renal Cell Carc... | Durvalumab Oleclumab | 18 Years - | University Health Network, Toronto | |
| Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Advanced Cutaneous Melanoma | NCT02535078 | Malignant Melan... | Tebentafusp (IM... durvalumab tremelimumab | 18 Years - | Immunocore Ltd | |
| Observational Study of Durvalumab in Patients With Non-small-cell Lung Cancer in the United Kingdom | NCT04667312 | Non-Small Cell ... | Durvalumab | 18 Years - | AstraZeneca | |
| Phase III Study to Determine Efficacy of Durvalumab in Stage II-III Non-small Cell Lung Cancer (NSCLC) After Curative Intent Therapy. | NCT04642469 | Carcinoma, Non-... | Durvalumab Placebo | 18 Years - 130 Years | AstraZeneca | |
| A Phase II Multicenter Study of Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI 4736) in Patients With Lymph Node Positive Urothelial Carcinoma of the Bladder | NCT05137262 | Urothelial Carc... Bladder Cancer | Abiraterone ace... Durvalumab Methotrexate Vinblastine Doxorubicin Hyd... Cisplatin | 18 Years - | M.D. Anderson Cancer Center | |
| Tumor Treating Fields for Locally Advanced NSCLC | NCT06124118 | Non Small Cell ... | carboplatin che... NovoTTF-200T (T... Durvalumab | 22 Years - | University of Utah | |
| Immunotherapy and SBRT for Metastatic Head and Neck Carcinomas | NCT03283605 | Head and Neck S... Metastatic Squa... | SBRT Durvalumab Tremelimumab | 18 Years - | Centre hospitalier de l'Université de Montréal (CHUM) | |
| An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Adults With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Patients With Acute Myeloid Leukemia (AML) | NCT02775903 | Leukemia, Myelo... Myelodysplastic... | Azacitidine Durvalumab | 18 Years - | Celgene | |
| Quick Start Durvalumab Following Chemoradiation for Stage III Nonsmall Cell Lung Cancer | NCT05696782 | Nonsmall Cell L... Unresectable No... | Durvalumab the EORTC Core ... COPD Assessment... Modified Medica... | 18 Years - | Wake Forest University Health Sciences | |
| Study of Durvalumab and Tremelimumab After Radiation for Microsatellite Stable Metastatic Colorectal Cancer Progressing on Chemotherapy | NCT03007407 | Colorectal Canc... | durvalumab Tremelimumab | 18 Years - | NSABP Foundation Inc | |
| Durvalumab and Consolidation SBRT Following Chemoradiation for Locally Advanced Stage III Non-Small Cell Lung | NCT03589547 | Stage III Non-s... | Durvalumab SBRT | 18 Years - | Brown University | |
| Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer | NCT06287775 | Extensive Stage... Stage IV Lung C... | Atezolizumab Biopsy Biospecimen Col... Computed Tomogr... Durvalumab Echocardiograph... Iadademstat Magnetic Resona... Multigated Acqu... | 18 Years - | National Cancer Institute (NCI) | |
| TRUDI: TDXD+Durva in HER2+/Low IBC | NCT05795101 | Invasive Breast... Inflammatory Br... HER2-positive B... HER2 Low Breast... Breast Cancer | Trastuzumab der... Durvalumab | 18 Years - | Dana-Farber Cancer Institute | |
| Durvalumab and Stereotactic Radiotherapy for Advanced NSCLC | NCT04786093 | Non Small Cell ... | Stereotactic ra... Durvalumab | 18 Years - | University of Texas Southwestern Medical Center | |
| PD-L1 ImagiNg to prediCt Durvalumab Treatment Response in HNSCC | NCT03829007 | Head and Neck C... | PD-L1 imaging Durvalumab | 18 Years - | Radboud University Medical Center | |
| Study of Durvalumab With Chemoradiotherapy for Women With Locally Advanced Cervical Cancer (CALLA) | NCT03830866 | Locally Advance... | Durvalumab Cisplatin Carboplatin external beam r... | 18 Years - 130 Years | AstraZeneca | |
| MOnaliZumab in Combination With durvAlumab (MEDI4736) Plus Platinum-based chemotheRapy for First-line Treatment of Extensive Stage Small Cell Lung Cancer | NCT05903092 | Small Cell Lung... SCLC Extensive Stage... | Durvalumab Monalizumab Carboplatin or ... Etoposide | 18 Years - | Hoosier Cancer Research Network | |
| A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer | NCT05221840 | Non-Small Cell ... | Durvalumab Oleclumab Monalizumab Placebo | 18 Years - | AstraZeneca | |
| Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer | NCT04628767 | Renal Pelvis an... | Biopsy Biospecimen Col... Cisplatin Computed Tomogr... Doxorubicin Hyd... Durvalumab Gemcitabine Hyd... Magnetic Resona... Methotrexate Pegfilgrastim Therapeutic Con... Vinblastine Sul... | 18 Years - | National Cancer Institute (NCI) | |
| Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients | NCT03737643 | Advanced Ovaria... | Bevacizumab Durvalumab Olaparib Placebo olapari... Durvalumab plac... Carboplatin+Pac... | 18 Years - 130 Years | AstraZeneca | |
| Durvalumab in Pediatric and Adolescent Patients | NCT02793466 | Solid Tumor Lymphoma Central Nervous... | Durvalumab; MED... | 1 Year - 17 Years | Children's Hospital Los Angeles | |
| SCION: SABR and Checkpoint Inhibition Of NSCLC | NCT04944173 | Non Small Cell ... Carcinoma, Non-... Non-small Cell ... Lung Cancer Lung Cancer Sta... Lung Adenocarci... Lung Squamous C... | Durvalumab Stereotactic Bo... Circulating Tum... | 18 Years - | University of British Columbia | |
| Pilot Study of Durvalumab and Vigil in Advanced Women's Cancers | NCT02725489 | Breast Cancer Ovarian Cancer Fallopian Tube ... Primary Periton... Uterine Cancer Cervical Cancer Endometrial Can... | Vigil Durvalumab | 18 Years - | Mary Crowley Medical Research Center | |
| Radiation and Durvalumab Immunotherapy As Neoadjuvant Treatment for MIBC | NCT04543110 | Bladder Cancer | Durvalumab Immune Modulati... | 18 Years - | Ottawa Hospital Research Institute | |
| Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer | NCT04699838 | Extensive Stage... | Cisplatin Carboplatin Etoposide Durvalumab Ceralasertib | 18 Years - | Big Ten Cancer Research Consortium | |
| Clinical Trial Evaluating FOLFIRI + Durvalumab vs FOLFIRI + Durvalumab and Tremelimumab in Second-line Treatment of Patients With Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma | NCT03959293 | Gastric Adenoca... Gastric Cancer | Durvalumab Tremelimumab FOLFIRI Protoco... | 18 Years - | Federation Francophone de Cancerologie Digestive | |
| Study of Durvalumab and Guadecitabine in Advanced Kidney Cancer | NCT03308396 | Advanced Kidney... Kidney Cancer Clear Cell Rena... | Guadecitabine Durvalumab | 18 Years - | Big Ten Cancer Research Consortium | |
| Durvalumab Combined With GemCis Neoadjuvant Therapy of Resectable Intrahepatic Cholangiocarcinoma With High Recurrence Risk | NCT05672537 | Durvalumab Intrahepatic Ch... Gemcis | Durvalumab Surgery Gemcitabine Cisplatin | 18 Years - 75 Years | Tianjin Medical University Cancer Institute and Hospital | |
| ......SMARTEST Trial...... | NCT05380713 | Mesothelioma, M... | Cyclophosphamid... Tremelimumab Durvalumab | 18 Years - 95 Years | University Health Network, Toronto | |
| Window of Opportunity Trial of Durvalumab (MEDI4736) to Identify Immune Dynamics in Operable Non-small Cell Lung Cancer (NSCLC) (MIRACLE) | NCT05206812 | Non Small Cell ... | durvalumab | 20 Years - | Yonsei University | |
| Durvalumab(MEDI4736) and AZD6738 Combination Therapy in Relapsed Small Cell Lung Cancer Subjects | NCT04361825 | Small Cell Lung... | Durvalumab | 18 Years - | Samsung Medical Center | |
| MEDI4736 With Selumetinib for KRAS Mutant Non-Small Cell Lung Cancer (NSCLC) | NCT03004105 | Malignant Neopl... Advanced Lung C... Recurrent Nonsm... | Selumetinib Durvalumab Phone Calls | 18 Years - | M.D. Anderson Cancer Center | |
| A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma | NCT02519348 | Hepatocellular ... | Tremelimumab Durvalumab Bevacizumab | 18 Years - 99 Years | MedImmune LLC | |
| WoO: Window of Opportunity Trial of Olaparib and Durvalumab in Histologically Proven EOC | NCT04644289 | Epithelial Ovar... | olaparib durvalumab | 18 Years - | AGO Research GmbH | |
| Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03) | NCT04379596 | Gastric Cancer | Fluorouracil (5... Capecitabine Durvalumab Oxaliplatin Trastuzumab Trastuzumab der... Cisplatin Pembrolizumab Volrustomig Rilvegostomig | 18 Years - 130 Years | AstraZeneca | |
| A French Real-life Study: EvaluatioN of durvALumab Utilization and Effectiveness for First Line Extensive Stage Small Cell Lung Cancer. | NCT05683977 | Small Cell Lung... | durvalumab | - | AstraZeneca | |
| A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients | NCT03706690 | Carcinoma, Non-... | Durvalumab Placebo | 18 Years - 130 Years | AstraZeneca | |
| A Trial of Durvalumab and Tremelimumab in Combination With SBRT in Patients With Metastatic Cancer | NCT03212469 | Head and Neck S... Lung Cancer Oesophageal Can... | Durvalumab Tremelimumab SBRT | 18 Years - | Gustave Roussy, Cancer Campus, Grand Paris | |
| Improve Checkpoint-blockade Response in Advanced Urothelial Cancer | NCT03871036 | Urothelial Carc... | Tremelimumab Durvalumab Paclitaxel | 18 Years - | The Netherlands Cancer Institute | |
| A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer. | NCT06284317 | Non Small Cell ... | Adjuvant durval... | 18 Years - | ETOP IBCSG Partners Foundation | |
| Trial of Local Cystoscopic Injection of Tremelimumab Plus Systemic Durvalumab for High Risk Non-Muscle Invasive Bladder Cancer | NCT05120622 | Bladder Cancer High-Risk Cance... Tremelimumab Durvalumab Non-muscle Inva... | Tremelimumab | - | University of British Columbia | |
| Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer | NCT02888743 | Metastatic Colo... Metastatic Lung... Stage IV Colore... Stage IV Lung N... Stage IVA Color... Stage IVB Color... | Durvalumab Radiation Thera... Tremelimumab | 18 Years - | National Cancer Institute (NCI) | |
| A Study of Canakinumab With Chemotherapy, Radiation Therapy, and Durvalumab in People With Lung Cancer | NCT04905316 | Non-small Cell ... | Canakinumab Durvalumab Radiation thera... Chemotherapy | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| RELEVANCE - RWE Study in Unresectable Non-Small Cell Lung Cancer (Stage III) in Canada | NCT05933044 | Non-small Cell ... | Durvalumab | 18 Years - 130 Years | AstraZeneca | |
| Durvalumab and Grid Therapy for Non-small Cell Lung Cancer in Progression During or After Treatment With PACIFIC Regimen | NCT05443971 | Lung Non-Small ... Stage III Lung ... | Durvalumab Radiation Thera... Biospecimen Col... | 18 Years - | Mayo Clinic | |
| Montreal Immune-Related Adverse Events (MIRAE) Study | NCT05139706 | Cancer Immune System D... Inflammatory Re... Autoimmune Dise... | 18 Years - 100 Years | Sir Mortimer B. Davis - Jewish General Hospital | ||
| Durvalumab And Radiation Therapy Followed by Adjuvant Durvalumab in Patients With Urothelial Cancer (T2-4 N0-2 M0) of the Bladder | NCT02891161 | Urothelial Canc... | durvalumab Radiation Thera... | 18 Years - | Big Ten Cancer Research Consortium | |
| Durvalumab and Tremelimumab With Platinum-based Chemotherapy in Intrahepatic Cholangiocarcinoma (ICC) | NCT04989218 | Cholangiocarcin... | Novel combinati... | 18 Years - 89 Years | University of Alabama at Birmingham | |
| Neoadjuvant Durvalumab and Tremelimumab Plus Radiation for High Risk Soft-Tissue Sarcoma | NCT03116529 | Soft Tissue Sar... | Combination Rad... | 18 Years - | University of Maryland, Baltimore | |
| CFI-400945 and Durvalumab in Patients With Advanced Triple Negative Breast Cancer | NCT04176848 | Breast Cancer | CFI-400945 Durvalumab | 18 Years - | Canadian Cancer Trials Group | |
| A Study of MEDI1191 in Sequential and Concurrent Combination With Durvalumab in Subjects With Advanced Solid Tumors | NCT03946800 | Solid Tumors Cancer | MEDI1191 Durvalumab | 18 Years - 101 Years | MedImmune LLC | |
| DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma | NCT04334759 | Mesothelioma Pleural Mesothe... Malignant Pleur... | Durvalumab Standard Chemot... Ipilimumab and ... | 18 Years - | PrECOG, LLC. | |
| Intensified Chemo-immuno-radiotherapy With Durvalumab for Stage III Non-Small Cell Lung Cancers | NCT04230408 | Lung Neoplasms | Durvalumab | 18 Years - | Latin American Cooperative Oncology Group | |
| Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma | NCT03376659 | Metastatic Colo... Colorectal Aden... Pancreatic Aden... Metastatic Panc... | Durvalumab CV301 Capecitabine Bevacizumab | 18 Years - | Georgetown University | |
| Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer | NCT04592913 | Gastrointestina... Esophagogastric... | Durvalumab FLOT chemothera... | 18 Years - 200 Years | AstraZeneca | |
| PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition and/or Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Chemotherapy Resistant Residual Triple Negative Breast Cancer | NCT03740893 | Breast Neoplasm | AZD6738 Olaparib Durvalumab | 18 Years - | Institute of Cancer Research, United Kingdom | |
| Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma | NCT04668300 | Metastatic Angi... Metastatic Dedi... Metastatic Oste... Recurrent Angio... Recurrent Dedif... Recurrent Osteo... Refractory Dedi... Refractory Oste... | Durvalumab Oleclumab | 12 Years - | M.D. Anderson Cancer Center | |
| Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer | NCT04699838 | Extensive Stage... | Cisplatin Carboplatin Etoposide Durvalumab Ceralasertib | 18 Years - | Big Ten Cancer Research Consortium | |
| Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations | NCT04521686 | Cholangiocarcin... Chondrosarcoma Glioma Any Solid Tumor | LY3410738 Gemcitabine Cisplatin Durvalumab | 18 Years - | Eli Lilly and Company | |
| Study to Evaluate the Safety and Pharmacokinetics of MEDI9090 in Subjects With Advanced Solid Tumors | NCT02900157 | Advanced Solid ... | MEDI9090 Durvalumab | 18 Years - 99 Years | MedImmune LLC | |
| Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract Cancer | NCT05239169 | Biliary Tract C... Intrahepatic Ch... Hilar Cholangio... Distal Cholangi... Gall Bladder Ca... | Durvalumab Tremelimumab Capecitabine | 18 Years - | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | |
| Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy | NCT03703297 | Small Cell Lung... | Durvalumab Tremelimumab Placebo | 18 Years - 130 Years | AstraZeneca | |
| Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver Cancer | NCT04605731 | BCLC Stage B He... BCLC Stage C He... Locally Advance... Stage III Hepat... Stage IIIA Hepa... Stage IIIB Hepa... Stage IV Hepato... Stage IVA Hepat... Stage IVB Hepat... Unresectable He... | Durvalumab Tremelimumab | 18 Years - | City of Hope Medical Center | |
| Durvalumab and Chemotherapy Induction Followed by Durvalumab and Radiotherapy in Large Volume Stage III NSCLC | NCT04765709 | Non-small Cell ... | durvalumab plus... Durvalumab plus... durvalumab | 18 Years - | Mario Negri Institute for Pharmacological Research | |
| Combination of Durvalumab and BVAC-C in Patients With HPV 16 or 18 Positive Cervical Cancer Failure to First-Line Platinum-based Chemotherapy | NCT04800978 | Cervical Cancer | BAVC-C+Durvalum... | 19 Years - | Samsung Medical Center | |
| A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC | NCT03819465 | Metastatic Non-... | Durvalumab Danvatirsen Oleclumab MEDI5752 Pemetrexed Carboplatin Gemcitabine Cisplatin Nab-paclitaxel AZD2936 | 18 Years - 130 Years | AstraZeneca | |
| A Clinical Trial of Durvalumab (MEDI4736) as 1st Line Therapy in Advanced Non-small Cell Lung Cancer Patients | NCT02879617 | Non-Small Cell ... | durvalumab | 18 Years - | Academic Thoracic Oncology Medical Investigators Consortium |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
